image
Healthcare - Medical - Devices - NASDAQ - US
$ 0.5149
-8.17 %
$ 1.92 M
Market Cap
-0.05
P/E
1. INTRINSIC VALUE

Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-invasive technologies for the treatment of symptoms caused by neurological disease or trauma. Its product, Portable Neuromodulation Stimulator (PoNS), is a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company is headquartered in Newtown, Pennsylvania.[ Read More ]

The intrinsic value of one HSDT stock under the base case scenario is HIDDEN Compared to the current market price of 0.515 USD, Helius Medical Technologies, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart HSDT

image
FINANCIALS
644 K REVENUE
-18.17%
-12.3 M OPERATING INCOME
16.87%
-8.85 M NET INCOME
37.11%
-10.4 M OPERATING CASH FLOW
27.21%
-29 K INVESTING CASH FLOW
-163.64%
1.08 M FINANCING CASH FLOW
-93.97%
51 K REVENUE
-71.98%
-4.07 M OPERATING INCOME
-24.46%
-3.69 M NET INCOME
-128.66%
-2.77 M OPERATING CASH FLOW
4.15%
0 INVESTING CASH FLOW
0.00%
-149 K FINANCING CASH FLOW
-2.64%
Balance Sheet Decomposition Helius Medical Technologies, Inc.
image
Current Assets 7.44 M
Cash & Short-Term Investments 5.18 M
Receivables 637 K
Other Current Assets 1.62 M
Non-Current Assets 254 K
Long-Term Investments 0
PP&E 230 K
Other Non-Current Assets 24 K
Current Liabilities 1.88 M
Accounts Payable 531 K
Short-Term Debt 90 K
Other Current Liabilities 1.26 M
Non-Current Liabilities 3.46 M
Long-Term Debt 24 K
Other Non-Current Liabilities 3.44 M
EFFICIENCY
Earnings Waterfall Helius Medical Technologies, Inc.
image
Revenue 644 K
Cost Of Revenue 583 K
Gross Profit 61 K
Operating Expenses 12.2 M
Operating Income -12.3 M
Other Expenses -3.42 M
Net Income -8.85 M
RATIOS
9.47% GROSS MARGIN
9.47%
-1905.12% OPERATING MARGIN
-1905.12%
-1374.22% NET MARGIN
-1374.22%
-376.60% ROE
-376.60%
-115.05% ROA
-115.05%
-509.72% ROIC
-509.72%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Helius Medical Technologies, Inc.
image
Net Income -8.85 M
Depreciation & Amortization 162 K
Capital Expenditures -29 K
Stock-Based Compensation 1.63 M
Change in Working Capital -311 K
Others -3.1 M
Free Cash Flow -10.4 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Helius Medical Technologies, Inc.
image
HSDT has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Helius Medical Technologies, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
74.4 K USD 1
9-12 MONTHS
Date Value Insider Amount Avg Price
11 months ago
Dec 01, 2023
Bought 4.15 K USD
ANDREEFF DANE
President and CEO
+ 643
6.448 USD
11 months ago
Nov 30, 2023
Bought 4.08 K USD
ANDREEFF DANE
President and CEO
+ 641
6.3704 USD
11 months ago
Dec 14, 2023
Bought 22.9 K USD
ANDREEFF DANE
President and CEO
+ 2827
8.095 USD
11 months ago
Dec 14, 2023
Bought 13 K USD
ANDREEFF DANE
President and CEO
+ 1603
8.095 USD
11 months ago
Dec 14, 2023
Bought 4.61 K USD
ANDREEFF DANE
President and CEO
+ 570
8.095 USD
11 months ago
Dec 01, 2023
Bought 7.31 K USD
ANDREEFF DANE
President and CEO
+ 1134
6.448 USD
11 months ago
Nov 30, 2023
Bought 7.2 K USD
ANDREEFF DANE
President and CEO
+ 1131
6.3704 USD
11 months ago
Dec 01, 2023
Bought 4.15 K USD
ANDREEFF DANE
President and CEO
+ 643
6.448 USD
11 months ago
Nov 30, 2023
Bought 4.08 K USD
ANDREEFF DANE
President and CEO
+ 641
6.3704 USD
11 months ago
Dec 01, 2023
Bought 1.48 K USD
ANDREEFF DANE
President and CEO
+ 229
6.448 USD
11 months ago
Nov 30, 2023
Bought 1.45 K USD
ANDREEFF DANE
President and CEO
+ 228
6.3704 USD
1 year ago
Aug 30, 2023
Bought 20.2 K USD
ANDREEFF DANE
President and CEO
+ 2646
7.6423 USD
1 year ago
Aug 30, 2023
Bought 12.7 K USD
ANDREEFF DANE
President and CEO
+ 1658
7.6423 USD
1 year ago
Aug 28, 2023
Bought 17.1 K USD
ANDREEFF DANE
President and CEO
+ 2688
6.3684 USD
1 year ago
Aug 28, 2023
Bought 10.7 K USD
ANDREEFF DANE
President and CEO
+ 1684
6.3684 USD
1 year ago
Aug 30, 2023
Bought 4.24 K USD
ANDREEFF DANE
President and CEO
+ 555
7.6423 USD
1 year ago
Aug 28, 2023
Bought 3.59 K USD
ANDREEFF DANE
President and CEO
+ 563
6.3684 USD
1 year ago
Aug 30, 2023
Bought 1.08 K USD
ANDREEFF DANE
President and CEO
+ 141
7.6423 USD
1 year ago
Aug 28, 2023
Bought 911 USD
ANDREEFF DANE
President and CEO
+ 143
6.3684 USD
1 year ago
Dec 16, 2022
Bought 6.38 K USD
ANDREEFF DANE
director: President and CEO
+ 25594
0.2492 USD
1 year ago
Dec 16, 2022
Bought 10.8 K USD
ANDREEFF DANE
director: President and CEO
+ 43266
0.2492 USD
1 year ago
Dec 16, 2022
Bought 2.21 K USD
ANDREEFF DANE
director: President and CEO
+ 8868
0.2492 USD
1 year ago
Dec 16, 2022
Bought 576 USD
ANDREEFF DANE
director: President and CEO
+ 2313
0.2492 USD
1 year ago
Nov 23, 2022
Bought 9.61 K USD
ANDREEFF DANE
director: President and CEO
+ 30841
0.3117 USD
1 year ago
Nov 23, 2022
Bought 13.1 K USD
ANDREEFF DANE
director: President and CEO
+ 42185
0.3117 USD
1 year ago
Nov 22, 2022
Bought 2.92 K USD
ANDREEFF DANE
director: President and CEO
+ 10300
0.2834 USD
1 year ago
Nov 23, 2022
Bought 3.15 K USD
ANDREEFF DANE
director: President and CEO
+ 10105
0.3117 USD
1 year ago
Nov 23, 2022
Bought 782 USD
ANDREEFF DANE
director: President and CEO
+ 2509
0.3117 USD
1 year ago
Nov 23, 2022
Bought 9.95 K USD
ANDREEFF DANE
director: President and CEO
+ 31921
0.3117 USD
1 year ago
Nov 23, 2022
Bought 13.8 K USD
ANDREEFF DANE
director: President and CEO
+ 44322
0.3117 USD
1 year ago
Nov 22, 2022
Bought 2.83 K USD
ANDREEFF DANE
director: President and CEO
+ 10000
0.2834 USD
1 year ago
Nov 23, 2022
Bought 3.26 K USD
ANDREEFF DANE
director: President and CEO
+ 10459
0.3117 USD
1 year ago
Nov 23, 2022
Bought 810 USD
ANDREEFF DANE
director: President and CEO
+ 2598
0.3117 USD
2 years ago
Nov 17, 2022
Bought 12.7 K USD
ANDREEFF DANE
director: President and CEO
+ 37464
0.3385 USD
2 years ago
Nov 17, 2022
Bought 18.2 K USD
ANDREEFF DANE
director: President and CEO
+ 53753
0.3385 USD
2 years ago
Nov 16, 2022
Bought 3.22 K USD
ANDREEFF DANE
director: President and CEO
+ 10000
0.3224 USD
2 years ago
Nov 17, 2022
Bought 4.16 K USD
ANDREEFF DANE
director: President and CEO
+ 12275
0.3385 USD
2 years ago
Nov 17, 2022
Bought 1.03 K USD
ANDREEFF DANE
director: President and CEO
+ 3049
0.3385 USD
2 years ago
Aug 24, 2022
Bought 15.1 K USD
ANDREEFF DANE
director: President and CEO
+ 23937
0.63 USD
2 years ago
Dec 17, 2021
Bought 20.1 K USD
ANDREEFF DANE
President and CEO
+ 3825
5.2528 USD
2 years ago
Dec 17, 2021
Bought 6.7 K USD
ANDREEFF DANE
President and CEO
+ 1275
5.2528 USD
2 years ago
Dec 17, 2021
Bought 15.9 K USD
MATHIESEN JEFFREY S
CFO and Treasurer
+ 3000
5.3098 USD
3 years ago
Nov 12, 2021
Bought 184 K USD
ANDREEFF DANE
President and CEO
+ 22960
8 USD
3 years ago
Nov 12, 2021
Bought 91.4 K USD
ANDREEFF DANE
President and CEO
+ 11430
8 USD
3 years ago
Nov 12, 2021
Bought 23.3 K USD
ANDREEFF DANE
President and CEO
+ 2910
8 USD
3 years ago
Nov 12, 2021
Bought 1.6 K USD
ANDREEFF DANE
President and CEO
+ 200
8 USD
3 years ago
Sep 15, 2021
Bought 79.6 K USD
ANDREEFF DANE
President and CEO
+ 5408
14.7222 USD
3 years ago
Sep 15, 2021
Bought 46 K USD
ANDREEFF DANE
President and CEO
+ 3125
14.7222 USD
3 years ago
Sep 15, 2021
Bought 17 K USD
ANDREEFF DANE
President and CEO
+ 1155
14.7222 USD
3 years ago
Sep 15, 2021
Bought 4.59 K USD
ANDREEFF DANE
President and CEO
+ 312
14.7222 USD
3 years ago
Sep 10, 2021
Bought 80.9 K USD
ANDREEFF DANE
President and CEO
+ 5408
14.9629 USD
3 years ago
Sep 10, 2021
Bought 46.8 K USD
ANDREEFF DANE
President and CEO
+ 3125
14.9629 USD
3 years ago
Sep 10, 2021
Bought 17.3 K USD
ANDREEFF DANE
President and CEO
+ 1155
14.9629 USD
3 years ago
Sep 10, 2021
Bought 4.67 K USD
ANDREEFF DANE
President and CEO
+ 312
14.9629 USD
3 years ago
Sep 08, 2021
Bought 48.1 K USD
ANDREEFF DANE
President and CEO
+ 3245
14.8262 USD
3 years ago
Sep 07, 2021
Bought 35.8 K USD
ANDREEFF DANE
President and CEO
+ 2407
14.8628 USD
3 years ago
Sep 08, 2021
Bought 27.8 K USD
ANDREEFF DANE
President and CEO
+ 1875
14.8262 USD
3 years ago
Sep 07, 2021
Bought 20.7 K USD
ANDREEFF DANE
President and CEO
+ 1390
14.8628 USD
3 years ago
Sep 08, 2021
Bought 10.3 K USD
ANDREEFF DANE
President and CEO
+ 693
14.8262 USD
3 years ago
Sep 07, 2021
Bought 7.64 K USD
ANDREEFF DANE
President and CEO
+ 514
14.8628 USD
3 years ago
Sep 08, 2021
Bought 2.77 K USD
ANDREEFF DANE
President and CEO
+ 187
14.8262 USD
3 years ago
Sep 07, 2021
Bought 2.07 K USD
ANDREEFF DANE
President and CEO
+ 139
14.8628 USD
4 years ago
May 15, 2020
Bought 30.2 K USD
ANDREEFF DANE
Director
+ 53969
0.56 USD
4 years ago
May 15, 2020
Bought 17.7 K USD
ANDREEFF DANE
Director
+ 31620
0.56 USD
4 years ago
May 15, 2020
Bought 6.36 K USD
ANDREEFF DANE
Director
+ 11359
0.56 USD
4 years ago
May 15, 2020
Bought 1.71 K USD
ANDREEFF DANE
Director
+ 3052
0.56 USD
4 years ago
May 14, 2020
Bought 15.1 K USD
ANDREEFF DANE
Director
+ 26985
0.56 USD
4 years ago
May 13, 2020
Bought 46.1 K USD
ANDREEFF DANE
Director
+ 80954
0.57 USD
4 years ago
May 14, 2020
Bought 8.85 K USD
ANDREEFF DANE
Director
+ 15810
0.56 USD
4 years ago
May 13, 2020
Bought 27 K USD
ANDREEFF DANE
Director
+ 47430
0.57 USD
4 years ago
May 14, 2020
Bought 3.18 K USD
ANDREEFF DANE
Director
+ 5679
0.56 USD
4 years ago
May 13, 2020
Bought 9.71 K USD
ANDREEFF DANE
Director
+ 17038
0.57 USD
4 years ago
May 14, 2020
Bought 855 USD
ANDREEFF DANE
Director
+ 1526
0.56 USD
4 years ago
May 13, 2020
Bought 2.61 K USD
ANDREEFF DANE
Director
+ 4578
0.57 USD
6 years ago
Jun 27, 2018
Bought 13.9 K USD
ANDREEFF DANE
Director
+ 1379
10.11 USD
6 years ago
Jun 26, 2018
Bought 13.9 K USD
ANDREEFF DANE
Director
+ 1379
10.1 USD
6 years ago
Jun 25, 2018
Bought 27.8 K USD
ANDREEFF DANE
Director
+ 2757
10.1 USD
6 years ago
Jun 27, 2018
Bought 8.26 K USD
ANDREEFF DANE
Director
+ 817
10.11 USD
6 years ago
Jun 26, 2018
Bought 8.25 K USD
ANDREEFF DANE
Director
+ 817
10.1 USD
6 years ago
Jun 25, 2018
Bought 16.5 K USD
ANDREEFF DANE
Director
+ 1634
10.1 USD
6 years ago
Jun 27, 2018
Bought 3.07 K USD
ANDREEFF DANE
Director
+ 304
10.11 USD
6 years ago
Jun 26, 2018
Bought 3.07 K USD
ANDREEFF DANE
Director
+ 304
10.1 USD
6 years ago
Jun 25, 2018
Bought 6.15 K USD
ANDREEFF DANE
Director
+ 609
10.1 USD
6 years ago
Apr 13, 2018
Bought 25 K USD
GRIFFIN THOMAS E
Director
+ 3346
7.47 USD
6 years ago
Apr 13, 2018
Bought 41 K USD
GRIFFIN THOMAS E
Director
+ 3346
12.25 USD
6 years ago
Dec 22, 2017
Bought 750 K USD
Walter Blane
Director
+ 382653
1.96 USD
6 years ago
Dec 22, 2017
Bought 937 K USD
Walter Blane
Director
+ 382653
2.45 USD
6 years ago
Dec 22, 2017
Bought 155 K USD
LaViscount Joyce N
CFO and COO
+ 79082
1.96 USD
6 years ago
Dec 22, 2017
Bought 155 K USD
LaViscount Joyce N
CFO and COO
+ 79082
1.96 USD
6 years ago
Dec 22, 2017
Bought 194 K USD
LaViscount Joyce N
CFO and COO
+ 79082
2.45 USD
6 years ago
Dec 22, 2017
Bought 194 K USD
LaViscount Joyce N
CFO and COO
+ 79082
2.45 USD
6 years ago
Dec 22, 2017
Bought 250 K USD
Deschamps Philippe
President and CEO
+ 127551
1.96 USD
6 years ago
Dec 22, 2017
Bought 312 K USD
Deschamps Philippe
President and CEO
+ 127551
2.45 USD
6 years ago
Dec 22, 2017
Bought 276 K USD
ANDREEFF DANE
Director
+ 141027
1.96 USD
6 years ago
Dec 22, 2017
Bought 163 K USD
ANDREEFF DANE
Director
+ 83147
1.96 USD
6 years ago
Dec 22, 2017
Bought 60.6 K USD
ANDREEFF DANE
Director
+ 30927
1.96 USD
6 years ago
Dec 22, 2017
Bought 346 K USD
ANDREEFF DANE
Director
+ 141027
2.45 USD
6 years ago
Dec 22, 2017
Bought 204 K USD
ANDREEFF DANE
Director
+ 83147
2.45 USD
6 years ago
Dec 22, 2017
Bought 75.8 K USD
ANDREEFF DANE
Director
+ 30927
2.45 USD
7 years ago
Nov 17, 2017
Bought 50.2 K USD
Walter Blane
Director
+ 20000
2.5125 USD
7 years ago
Nov 16, 2017
Bought 48.1 K USD
Walter Blane
Director
+ 20000
2.4045 USD
7 years ago
Nov 13, 2017
Bought 30.7 K USD
ANDREEFF DANE
Director
+ 13790
2.225 USD
7 years ago
Nov 10, 2017
Bought 117 K USD
ANDREEFF DANE
Director
+ 45233
2.5914 USD
7 years ago
Nov 09, 2017
Bought 89.5 K USD
ANDREEFF DANE
Director
+ 33097
2.704 USD
7 years ago
Nov 13, 2017
Bought 18.2 K USD
ANDREEFF DANE
Director
+ 8171
2.225 USD
7 years ago
Nov 10, 2017
Bought 69.4 K USD
ANDREEFF DANE
Director
+ 26800
2.5914 USD
7 years ago
Nov 09, 2017
Bought 53 K USD
ANDREEFF DANE
Director
+ 19610
2.704 USD
7 years ago
Nov 13, 2017
Bought 6.76 K USD
ANDREEFF DANE
Director
+ 3039
2.225 USD
7 years ago
Nov 10, 2017
Bought 25.8 K USD
ANDREEFF DANE
Director
+ 9967
2.5914 USD
7 years ago
Nov 09, 2017
Bought 19.7 K USD
ANDREEFF DANE
Director
+ 7293
2.704 USD
9 years ago
Sep 10, 2015
Bought 9.96 K USD
STRAW EDWARD M
Director
+ 12500
0.797 USD
7. News
Helius Medical Technologies, Inc. to Present at the 2024 ThinkEquity Conference NEWTOWN, Pa., Oct. 18, 2024 – PRISM MediaWire – Helius Medical Technologies, Inc. prismmediawire.com - 4 weeks ago
Helius Medical Technologies, Inc. to Present at the 2024 ThinkEquity Conference NEWTOWN, Pa., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (“Helius” or the “Company”) [Nasdaq: HSDT], a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that it plans to participate in The ThinkEquity Conference on October 30, 2024, at the Mandarin Oriental Hotel in New York. globenewswire.com - 4 weeks ago
Helius Medical Technologies, Inc. Announces Reimbursement Payment Determination Updates from CMS for its Portable Neuromodulation Stimulator (PoNS®) Controller and Mouthpiece -- Reimbursement Determination for the PoNS Mouthpiece (HCPCS code A4594) set at $2,963.30 on Lump Sum Payment to be challenged by Helius -- -- National Reimbursement Payment Determination from CMS for its PoNS Controller Deferred to the Next Cycle -- globenewswire.com - 1 month ago
Helius Medical Technologies, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) NEWTOWN, Pa., Aug. 16, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that, effective August 14, 2024, its independent directors approved equity awards under Helius' 2021 Inducement Plan, as a material inducement to three individuals entering into employment with the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4), which also requires a public announcement of equity awards that are not made under a stockholder approved equity plan. globenewswire.com - 3 months ago
Helius Medical Technologies, Inc. (HSDT) Q2 2024 Earnings Call Transcript Helius Medical Technologies, Inc. (NASDAQ:HSDT ) Q2 2024 Results Conference Call August 12, 2024 4:30 PM ET Company Participants Michelle Bilski - IR Dane Andreeff - President and CO Jeff Mathiesen - CFO Conference Call Participants Anthony Vendetti - Maxim Group Operator Good day, and thank you for standing by. Welcome to the Helius Medical Technologies Second Quarter 2024 Earnings Conference Call [Operator Instructions]. seekingalpha.com - 3 months ago
Helius Medical Technologies, Inc. Reports Second Quarter 2024 Financial Results NEWTOWN, Pa., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced results for the quarter ended June 30, 2024. globenewswire.com - 3 months ago
Helius Medical Technologies, Inc. to Release Second Quarter 2024 Financial Results on August 12, 2024 NEWTOWN, Pa., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that the Company will release its second quarter 2024 financial results on Monday, August 12, 2024, after the market closes. globenewswire.com - 3 months ago
Helius Medical Technologies, Inc. Completes Site Participation Enrollment for its U.S. Registrational Program in Stroke -- Inclusion of the top neurorehabilitation centers REHABOLOGYM, Neurology Center of New England, and MGH Institute of Health Professions completes site participation enrollment for the U.S. registrational program in stroke -- -- In Canada, an additional study on the use of Portable Neuromodulation Stimulator (PoNS®) Therapy to treat stroke has started to support Canadian reimbursement and U.S. approval for stroke -- globenewswire.com - 5 months ago
Helius Medical Technologies, Inc. to Present at the Spring MicroCap Rodeo Conference NEWTOWN, PA / ACCESSWIRE / May 31, 2024 / Helius Medical Technologies, Inc., (Nasdaq:HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that it will participate in the Spring MicroCap Rodeo Conference to be held on Thursday, June 6th in NYC. Dane Andreeff, CEO, will attend the conference and plans to discuss: Pursuit of a stroke authorization in the U.S. for its Portable Neuromodulation Stimulator (PoNS®) device with the U.S. Food and Drug Administration (FDA); Helius' partnership with Lovell® Government Services to make PoNS available to federal healthcare systems, including the U.S. Department of Veterans Affairs (VA) and Department of Defense (DoD). accesswire.com - 5 months ago
Helius Medical Technologies to Exhibit at 2024 CMSC Annual Meeting, Marking a Year of Achievements: Making PoNS More Available to People with MS Company Will Highlight Major Milestones on Accessibility and Reimbursement Fronts Company Will Highlight Major Milestones on Accessibility and Reimbursement Fronts globenewswire.com - 5 months ago
Helius Medical Technologies, Inc. Announces PoNS® Is Now Available on the Veterans Affairs (VA) Federal Supply Schedule (FSS) and General Services Administration (GSA) Advantage Contracts -- Approval provides U.S. veterans and other U.S. government agency employees who suffer gait and balance impairment due to multiple sclerosis (MS) access to the only portable neurostimulation therapy with the potential to generate neuroplasticity -- NEWTOWN, Pa., May 20, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced the Company's Portable Neuromodulation Stimulator (PoNS®) device has been approved for inclusion on Lovell Government Services' (“Lovell”) Veterans Affairs (VA) Federal Supply Schedule (FSS) and General Services Administration (GSA) Advantage contracts. globenewswire.com - 5 months ago
Helius Medical Technologies, Inc. (HSDT) Q1 2024 Earnings Call Transcript Helius Medical Technologies, Inc. (NASDAQ:HSDT ) Q1 2024 Results Conference Call May 13, 2024 4:30 PM ET Company Participants Michelle Bilski - Investor Relations-In-Site Communications Dane Andreeff - President and Chief Executive Officer Jeff Mathiesen - Chief Financial Officer Conference Call Participants Nicholas Sherwood - Maxim Group Operator Good day, and thank you for standing by. Welcome to the Helius Medical Technologies First Quarter 2024 Earnings Conference Call. seekingalpha.com - 6 months ago
8. Profile Summary

Helius Medical Technologies, Inc. HSDT

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 1.92 M
Dividend Yield 0.00%
Description Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-invasive technologies for the treatment of symptoms caused by neurological disease or trauma. Its product, Portable Neuromodulation Stimulator (PoNS), is a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company is headquartered in Newtown, Pennsylvania.
Contact 642 Newtown Yardley Road, Newtown, PA, 18940 https://heliusmedical.com
IPO Date June 27, 2014
Employees 22
Officers Mr. Dane Carl Andreeff President, Chief Executive Officer & Director Dr. Antonella Favit-Van Pelt M.D., Ph.D. Chief Medical Officer Mr. Jeffrey S. Mathiesen CPA Chief Financial Officer, Treasurer, Secretary & Director Mr. Lawrence Picciano Senior Vice President of Engineering, Quality & Regulatory Affairs